Drug Trial Radar · NCT02052596
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Last checked: Nov 20, 2026Latest source record: Apr 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
935
Actual
Start
Feb 7, 2014
Primary completion
Jun 16, 2015
Study completion Apr 21, 2016
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to administration of vaccines separately.
Conditions
- Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173ABiological
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
BoostrixBiological
1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A GroupTime frame: At 1 month post-Dose 2 (Month 3)
- Antibody Concentrations Against Glycoprotein E (Anti-gE)Time frame: At 1 month post-Dose 2 (Month 3 for GSK1437173A Group adn Month 5 for Control Group)
- Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) AntigensTime frame: At 1 month post-Dose 1 (Month 1)
- Antibody Concentrations Against Diphteria (Anti-D) and Tetanus (Anti-T) AntigensTime frame: At 1 month post-Dose 1 (Month 1)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
San Diego, California
GSK Investigational Site
Stockbridge, Georgia
GSK Investigational Site
Meridian, Idaho
GSK Investigational Site
Lewiston, Maine
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Salisbury, North Carolina
GSK Investigational Site
Uniontown, Pennsylvania
GSK Investigational Site
Warwick, Rhode Island
GSK Investigational Site
Greer, South Carolina
GSK Investigational Site
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.